Spelling suggestions: "subject:"bingle nucleotide polymorphism."" "subject:"bringle nucleotide polymorphism.""
111 |
Analyser le gène PKC-2 chez Caernorhabditis elegans et crible les mutants contre sérotonine chez le C. elegans souche pkc-2 (ok328) / Analysis of pkc-2 gene of Caenorhabaditis elegans and screen for serotonin resistant mutant in pkc-2(ok328) backgroundQian, Yu 28 September 2009 (has links)
La myopathie de Duchenne est une maladie génétique qui se caractérise principalement par une dégénérescence progressive des muscles squelettiques dont la cause est l’absence de dystrophine fonctionnelle dans les muscles. A ce jour, il n’existe toujours pas de traitement efficace contre ces maladies. Comme le plus grand gène connu chez l’Homme, la dystrophine code pour une protéine de 427kDa. La protéine connecte l’actine avec le DAPC (Dystrophin Associated Protein Complex) dans les muscles striés. Pour l’instant, il y a 3 hypothèses concernant le mécanisme du DMD. L’absence de la dystrophine peut supprimer le lien physique entre les protéines structurales de la membrane basale (laminines) et les protéines structurales du cytosquelette (filaments intermédiaires et actine), ou la distribution et la fonction des canaux ioniques, ou des voies de signalisation nécessaires à la survie du muscle. Caenorhabditis elegans ne possède qu’un homologue du gène de la dystrophine humaine, le gène dys-1. La protéine DYS-1 présente 37% d’homologie avec la dystrophine humaine. Le double mutant dys-1(cx18) ; hlh-1(cc561) présente une forte dégénérescence musculaire. Comme le sarcomère de C. elegans ressemble au sarcomère de mammifère, C. elegans est modèle pertinent d’étude la maladie. En vue de comprendre la raison du DMD chez les mammifères et chez les vers, le groupe L. SEGALAT a effectué des cribles pour identifier les molécules et les gènes qui peuvent supprimer la dégénérescence musculaire. On a trouvé un gène pkc-2 qui est capable de supprimer la dégénérescence musculaire chez C. elegans. La protéine PKC-2 est l’orthologue de la Protein Kinase C Alpha (PKC) humaine et appartient à la famille du serine/threonine protéine kinase. Afin d’étudier la fonction du gène pkc-2, on a analysé l’expression du gène avec les construits différents in vivo et a utilisé la technique de double-hybride dans la levure. De plus, le crible par EMS (éthane méthyle sulfonâtes) a identifié une molécule sérotonine (5-HT) qui est un neuromédiateur, et supprime partiellement la dégénérescence musculaire des doubles mutants dys-1; hlh-1. La sérotonine a aussi un effet fort sur le mutant pkc-2(ok328), puisqu’elle provoque un phénotype blister. Ça nous permet de rechercher le lien entre la signalisation sérotoninergique et pkc-2. Le crible génétique peut contribuer à la connaissance du rôle pkc-2. […]. Elle sert aussi de plate-forme de voie de signalisation intracellulaire. L’identification de Y59A8A.3 propose la possibilité que pkc-2 modifie la filamin A par l’intermédiaire de la filamin A interacting protéine 1. Le crible génétique par EMS pour rechercher des suppresseurs de l’effet blister de la sérotonine sur les mutants pkc-2(ok328) a donné 8 candidats sur 5000 F1s : cx253, cx254, cx259, cx263, cx267, cx268, cx270, cx276. Les mutations ont été localisées sur les chromosomes par SNP mapping avec une souche de C. elegans très polymorphe, mais le temps a manqué pour leur identification exacte. L’expérience valide notre approche à étudier le lien entre la signalisation sérotoninergique et pkc-2. En résumé, le but de la thèse était de rechercher la fonction du gène pkc-2 dans les mécanismes moléculaires conduisant à la nécrose musculaire en absence de dystrophine. Les résultats présentés dans la thèse apportent des réponses aux questions fondamentales sur pkc-2 et aussi demandent des expériences supplémentaires afin de élucider plus avant les mécanismes de la dégénérescence musculaire dystrophine-dépendante. / Duchenne Muscular Dystrophy (DMD) is an X-linked progressive muscle disease which is caused by mutations in the dystrophin gene. Until now, there is no effective therapy for DMD. As the largest gene in human beings, it produces a 427-kDa cytoskeleton protein: Dystrophin. Dystrophin links actin and dystrophin associated protein complex (DAPC) in muscles. Currently, there are 3 hypotheses to explain the mechanisms of DMD. They suggest that the absence of dystrophin could lead to periodic muscle cell membrane ruptures, or affect the distribution and function of ion channels, or perturb signal transduction pathways. In Caenorhabditis elegans, there is only one homologue of mammalian dystrophin gene named dys-1, and the nematode protein DYS-1 presents 37% similar to the human one. The double mutant dys-1; hlh-1 exhibits a severe progressive muscle degeneration. The protein composition of the sarcomere has been studied and it has revealed a high degree of similarity with mammalian sarcomere. These allow C. elegans be a relevant animal model to study DMD.To understand why the lack of dystrophin induces muscle degeneration in mammals and worms, and to find new drugs that might help in reducing muscle degeneration, L. Ségalat and his coworkers performed several screens for drugs and genes suppressing muscle degeneration. An interesting gene pkc-2 came out and was considered as a possible regulator in the process of muscle degeneration in C. elegans. The protein that is encoded by this gene in C. elegans is an orthologous of the human gene Protein Kinase C Alpha (PKC), which belongs to the family of serine/threonine specific protein kinases. To study the function of pkc-2, we generated different recombinant constructs, analyzed the expression pattern of pkc-2 with immunocytochemistry, and performed yeast two-hybrid to search for PKC-2 binding partners. In addition, a neurotransmitter serotonin (5-HT) was found by drug screening to be an active blocker of striated muscle degeneration. As C. elegans lacking PKC-2 displays a severe blister phenotype in exogenous 5-HT, studying the correlation between PKC-2 and 5-HT therefore seems to be an opportunity to explore the reasons of muscle degeneration. A genetic screen with EMS (ethane methyl sulfonate) to search serotonin resistant mutant in strain pkc-2 (ok328) would help us study further about the role of pkc-2.In this thesis, different clones myo3::pkc-2 and pkc-2::gfp were made to inject into wild-type animals. The results revealed that pkc-2 expressed intensely in neurons and pharynx, but was not found in body-wall muscles. Mutants dys-1;hlh-1 fed with pkc-2 RNAi did not reduce muscle degeneration statistically comparing to triple mutant pkc-2;dys-1;hlh-1. This indicated that PKC-2 may be dominantly acting in neurons. A yeast two-hybrid screen identified the gene Y59A8A.3, which is a homologue to mammalian filamin A interacting protein 1 isoform 3, as a binding partner of PKC-2. Filamin A is a cytoskeleton protein, anchoring various trans-membrane proteins to the actin cytoskeleton and may also function as an important signaling scaffold. The result suggested that PKC-2 may therefore modulate filamin A activity through the filamin interacting protein 1. Genetic screen by EMS presented 8 candidates named cx253, cx254, cx259, cx263, cx267, cx268, cx270, cx276, which were mapped on chromosomes by SNP mapping using a polymorphic C. elegans strain, but time was too short to identify these genes formally. The experiment also offered possibilities of searching links between PKC-2 and serotonin pathways.In summary, this work studied the gene pkc-2 in order to reveal the function of PKC-2 and its involvement in muscle degeneration. The present results answered some questions about pkc-2, and needed further researches to elucidate the in vivo role of PKC-2 protein and its interaction with other proteins in the mechanism of muscle dystrophy in C. elegans.
|
112 |
The definition of multilocus haplotype blocks and common diseasesNothnagel, Michael 06 January 2005 (has links)
Bisherige Methoden der Haplotyp-Block-Definition zielen entweder auf abwesende Rekombinationsereignisse oder eine effiziente Beschreibung genomischer Variation. Die vorliegende Arbeit definiert Blöcke von Single Nucleotide Polymorphisms (SNP) als Gebiete erhöhten Kopplungsungleichgewichtes (LD). Für dieses Ziel wird ein neues, entropie-basiertes Maß für LD zwischen multiplen Markern/Loci (Normalized Entropy Difference) entwickelt und als eine Multilocus-Erweiterung des paarweisen Maßes r2 charakterisiert. Ein zugehöriger Algorithmus für die Block-Definition wird vorgeschlagen. Seine Evaluierung an einem Datensatz des menschlichen Chromosoms 12 vom Internationalen Haplotype Map Projekt zeigt die Nützlichkeit der abgeleiteten Blöcke in Hinblick auf verschiedene Eigenschaften, einschließlich ihrer chromosomalen Coverage und der Anzahl sowie des Anteils der häufigen Block-Haplotypen. Der wesentliche Einfluß der SNP-Dichte auf die zu entdeckenden LD- und Blockstrukturen wird demonstriert. Der Erfolg von Assoziationsstudien in komplexen Erkrankungen mit Block-Haplotypen als multiallelischen Markern wird davon abhängen, ob die Common Variants/Common Diseases (CV/CD) Hypothese für solche Erkrankungen erfüllt ist. / Current approaches to haplotype block definition target either absent recombination events or the efficient description of genomic variation. This thesis aims to define blocks of single nucleotide polymorphisms (SNP) as areas of elevated linkage disequilibrium (LD). To this end, a new entropy-based measure for LD between multiple markers/loci, the Normalized Entropy Difference, is developed and is characterized as a multilocus extension of the pairwise measure r2. A corresponding algorithm for the block definition is proposed. Its evaluation on a data set of human chromosome 12 from the International Haplotype Map project proves the usefulness of the derived blocks with respect to several features, including their chromosomal coverage and the number and portion of common block haplotypes. The critical role of the SNP density for detectable LD and block structure is demonstrated. The success of association studies in common diseases with block haplotypes serving as multi-allelic markers will depend on whether the Common Variants/Common Diseases (CV/CD) hypothesis holds true for those diseases.
|
113 |
Genetic Analysis of Quantitative Traits Using Domestic Animals : A Candidate Gene and Genome Scanning ApproachPark, Hee-Bok January 2004 (has links)
<p>Domestication has led to genetic changes that affect quantitative traits in farm animals. Both candidate gene analysis using association tests and genome scans based on linkage analysis have been performed to understand the molecular basis underlying quantitative genetic variation in horses, pigs and chickens. To test a possible association of polymorphisms in the <i>PRKAG3</i> gene, previously found to be associated with excess glycogen content in pig skeletal muscle, with quantitative traits in the horse, the major coding part of the equine <i>PRKAG3</i> sequence was identified. Bioinformatic characterization of the equine <i>PRKAG3</i> gene was conducted. A single nucleotide polymorphism (SNP) causing a missense mutation (Pro258Leu) was found. Screening this SNP showed that the Leu258 allele was more frequent in breeds with heavy muscularity. To assess previously reported associations between polymorphisms in the <i>MC4R</i> gene and obesity-related traits further, we conducted linkage analysis between the <i>MC4R</i> locus and fatness-related traits using a Wild BoarxLarge White intercross. No significant association between segregation at the <i>MC4R</i> locus and fatness was detected in this pedigree. A genome scan of quantitative trait loci (QTLs) has been performed in an intercross between chicken lines divergently selected for growth. Divergent parental lines have been established by selecting for high and low 56-day body weight for over 40 generations. The selection has led to approximately a 9-fold difference in 56-day body weight between lines and resulted in correlated responses for a number of traits including appetite, immune response, body composition and metabolic traits. Phenotypic data on growth and other correlated traits were collected from more than 800 F2 individuals. Genome scans using 145 markers on 26 linkage groups have identified QTLs affecting growth and correlated responses to selection for 56-day body weight. No major QTL explaining a large portion of phenotypic variation in growth was revealed in this study. </p>
|
114 |
Analyse von Single Nucleotide Polymorphisms an Glas-OberflächenSchwonbeck, Susanne January 2004 (has links)
Ziel der vorliegenden Arbeit war die Entwicklung einer SNP-Genotypisierungsmethode
mit auf Mikroarrays immobilisierten PCR-Produkten. Für die Analyse wurde
ein faseroptischer Affinitätssensor bzw. ein Durchfluss-Biochip-Scanner
mit integrierter Fluoreszenzdetektion verwendet. An den immobilisierten
Analyten (PCR-Produkten) wurde eine Fluoreszenzoligonukleotidsonde hybridisiert
und anschließend die Dissoziation der Sonde im Fluss verfolgt. Die Diskriminierung
von Wildtyp- und Mutanten-DNA erfolgte durch die kinetische Auswertung
der Dissoziationskurven sowie durch die Analyse der Fluoreszenzintensität.
<br>
<br>
Die Versuche am faseroptischen Affinitätssensor zeigten, dass DNA-DNA-Hybride
sowohl von Oligonukleotiden als auch von PCR-Produkten ein typisches Dissoziationsverhalten
aufweisen, wobei fehlgepaarte Hybride eine signifikant schnellere Dissoziation
zeigen als perfekt passende Hybride. Dieser Geschwindigkeitsunterschied
lässt sich durch den Vergleich der jeweiligen kinetischen Geschwindigkeitskonstanten
kD quantitativ erfassen. </p>
<p>Da die Kopplung des Analyten an der Chipoberfläche sowie die Hybridisierungs-
und Dissoziationsparameter essentiell für die Methodenentwicklung war,
wurden die Parameter für ein optimales Spotting und die Immobilisierung
von PCR-Produkten ermittelt. Getestet wurden die affine Kopplung von biotinylierten
PCR-Produkten an Streptavidin-, Avidin- und NeutrAvidin-Oberflächen sowie
die kovalente Bindung von phosphorylierten Amplifikaten mit der EDC/Methylimidazol-Methode.
Die besten Ergebnisse sowohl in Spotform und -homogenität als auch im
Signal/Rausch-Verhältnis wurden an NeutrAvidin-Oberflächen erreicht. </p>
<p>Für die Etablierung der Mikroarray-Genotypisierungsmethode durch kinetische
Analyse nach einem Hybridisierungsexperiment wurden Sondenlänge, Puffersystem,
Spotting-Konzentration des Analyten sowie Temperatur optimiert. Das Analysensystem
erlaubte es, PCR-Produkte mit einer Konzentration von 250 ng/µl in einem
HEPES-EDTA-NaCl-Puffer auf mit NeutrAvidin beschichtete Glasträger zu
spotten. In den anschließenden Hybridisierungs- und Dissoziationsexperimenten
bei 30 °C konnte die Diskriminierung von homocygoter Wildtyp- und homocygoter
Mutanten- sowie heterocygoter DNA am Beispiel von Oligonukleotid-Hybriden
erreicht werden. </p>
<p>In einer Gruppe von 24 homocygoten Patienten wurde ein Polymorphismus
im SULT1A1-Gen analysiert. Sowohl durch kinetische Auswertung als auch
mit der Analyse der Fluoreszenzintensität wurde der Genotyp der Proben
identifiziert. Die Ergebnisse wurden mit dem Referenzverfahren, der Restriktionschnittstellenanalyse
(PCR-RFLP) validiert. Lediglich ein Genotyp wurde falsch bestimmt, die
Genauigkeit lag bei 96%. </p>
<p>In einer Gruppe von 44 Patienten wurde der Genotyp eines SNP in der Adiponectin-Promotor-Region
untersucht. Nach Vergleich der Analysenergebnisse mit denen eines Referenzverfahrens
konnten lediglich 14 der untersuchten Genotypen bestätigt werden. Ursache
für die unzureichende Genauigkeit der Methode war vor allem das schlechte
Signal/Rausch-Verhältnis.</p>
<p> Zusammenfassend kann gesagt werden, dass das in dieser Arbeit entwickelte
Analysesystem für die Genotypisierung von Einzelpunktmutationen geeignet
ist, homocygote Patientenproben zuverlässig zu analysieren. Prinzipiell
ist das auch bei heterocygoter DNA möglich. Da nach aktuellem Kenntnisstand
eine SNP-Analysemethode an immobilisierten PCR-Produkten noch nicht veröffentlicht
wurde, stellt das hier entwickelte Verfahren eine Alternative zu bisher
bekannten Mikroarray-Verfahren dar. Als besonders vorteilhaft erweist
sich der reverse Ansatz der Methode. </p>
<p>Der hier vorgestellte Ansatz ist eine kostengünstigere und weniger hoch
dimensionierte Lösung für Fragestellungen beispielsweise in der Ernährungswissenschaft,
bei denen meist eine mittlere Anzahl Patienten auf nur einige wenige SNPs
zu untersuchen ist. Wenn es gelingt, durch die Weiterentwicklung der Hardware
bzw. weiterer Optimierung, eine Verbesserung des Signal/Rausch-Verhältnisses
und damit die Diskriminierung von heterocygoter DNA zu erreichen, kann
diese Methode zukünftig bei der Analyse von mittelgroßen Patientengruppen
alternativ zu anderen Genotypisierungsmethoden verwendet werden. / The aim of this thesis was the development of a SNP genotyping method
involving PCR products immobilised on microarrays. For the analysis a fibre
optic affinity biosensor and a flow-through biochip scanner were used.
Fluorescent probes were hybridized with the immobilised PCR products. In
order to start the dissociation process the surface was rinsed with buffer
and the fluorescence intensity was measured.
<br><br>
Two different cases were studied: First, the full-matched DNA hybrid
(wildtyp single strand with complementary wildtype single strand), second
the mis-matched hybrid (wildtype single strand and mutant single strand).
After determinating the reaction rates (kD) as kinetic parameter the kD
values of both cases were compared. The experiments showed a significant
difference in the kD value of the full- and the mis-match hybrids.
Therefore, mutant and wildtype DNA were discriminated by kinetic analysis
of the dissociation process and analysis of the fluorescence intensity.
<br><br>
To set up the complete analysis process the reaction parameters like
coupling of the PCR products had to be optimised. Both affininty coupled
(streptavidin, neutravidin, avidin - biotin) and covalent methods
(EDC/methylimidazol) were carried out. Best results in spot homogeinity and
spot appearance were obtained with coupling of biotinylated PCR products on
neutravidin coated chip surfaces. Additionally, the length of the probe,
the spotting concentration, the spotting buffer and the reaction
temperature were optimised. In the optimised analysis PCR products (250
µg/µl) were spotted onto neutravidin coated surfaces. The hybridisation
<br><br>
and dissociation processes were carried out at 30°C. A HEPES-EDTA-NaCl
buffer was used for spotting, diluting of the fluorescent probe and rinsing
the microarray surface. A fluorescent probe was used with 13 nucleotides in
length. The mis- or full-matching base indicating the polymorphism was
located in the center position of the probe.
<br><br>
The analysis system was tested with the genomic DNA of a group of 24
homocygote individuals with a SNP in the SULT1A1 gene region. The
hybridisation and dissociation processes were carried out and the reaction
rates were determinated. Subsequently after the analysis in the
flow-through biochip scanner the fluorescence intensity of the
<br><br>
spots were measured. The results showed very good comparability with
results of a PCR-RFLP analysis (one false genotype). Additionally, a group
of 44 heterocygote DNA samples with one SNP in the adiponectin promotor
region were also genotyped. Compared to a reference method only 14
genotypes were correctly determined. This was mostly due to a low
signal-noise-ratio and needs to be further investigated.
<br><br>
Besides the problem in analysing heterocygote DNA samples the developed
analysis system is very useful for genotyping SNP in homocygote DNA
samples. The successful analysis of heterocygote sample is principally
possible and with further investigations/optimisation, a better analysis
should be possible.
<br><br>
The most important advantage of the developed method is the reverse
approach of binding PCR products at the surface instead of
oligonucleotides. This allows the parallel genotyping of several
individuals. Other advantages include low costs and medium sized dimensions
in terms of throughput.
|
115 |
Genetic Analysis of Quantitative Traits Using Domestic Animals : A Candidate Gene and Genome Scanning ApproachPark, Hee-Bok January 2004 (has links)
Domestication has led to genetic changes that affect quantitative traits in farm animals. Both candidate gene analysis using association tests and genome scans based on linkage analysis have been performed to understand the molecular basis underlying quantitative genetic variation in horses, pigs and chickens. To test a possible association of polymorphisms in the PRKAG3 gene, previously found to be associated with excess glycogen content in pig skeletal muscle, with quantitative traits in the horse, the major coding part of the equine PRKAG3 sequence was identified. Bioinformatic characterization of the equine PRKAG3 gene was conducted. A single nucleotide polymorphism (SNP) causing a missense mutation (Pro258Leu) was found. Screening this SNP showed that the Leu258 allele was more frequent in breeds with heavy muscularity. To assess previously reported associations between polymorphisms in the MC4R gene and obesity-related traits further, we conducted linkage analysis between the MC4R locus and fatness-related traits using a Wild BoarxLarge White intercross. No significant association between segregation at the MC4R locus and fatness was detected in this pedigree. A genome scan of quantitative trait loci (QTLs) has been performed in an intercross between chicken lines divergently selected for growth. Divergent parental lines have been established by selecting for high and low 56-day body weight for over 40 generations. The selection has led to approximately a 9-fold difference in 56-day body weight between lines and resulted in correlated responses for a number of traits including appetite, immune response, body composition and metabolic traits. Phenotypic data on growth and other correlated traits were collected from more than 800 F2 individuals. Genome scans using 145 markers on 26 linkage groups have identified QTLs affecting growth and correlated responses to selection for 56-day body weight. No major QTL explaining a large portion of phenotypic variation in growth was revealed in this study.
|
116 |
Functional Analysis of the TRIB1 Locus in Coronary Artery DiseaseDouvris, Adrianna 21 July 2011 (has links)
The TRIB1 locus (8q24.13) is a novel locus associated with plasma TGs and CAD risk. Trib1 is a regulator of MAPK activity, and has been shown to regulate hepatic lipogenesis and VLDL production in mice. However, the functional relationship between common SNPs at the TRIB1 locus and plasma lipid traits is unknown; TRIB1 has not been identified as an eQTL. This cluster of SNPs falls within an intergenic region 25kb to 50kb downstream of the TRIB1 coding region. By phylogenetic footprinting analysis and DNA genotyping, we identified an evolutionarily conserved region (CNS1) within the risk locus that harbours two common SNPs in tight LD with GWAS risk SNPs and significantly associated with CAD. We investigated the regulatory function of CNS1 by luciferase reporter assays in HepG2 cells and demonstrate that this region has promoter activity. In addition, the rs2001844 risk allele significantly reduces luciferase activity, suggesting that altered expression of the EST-based gene may be associated with plasma TGs. We identified an EST within the risk locus directly downstream of CNS1. We performed 5'/3' RACE using HepG2 RNA, identified multiple variants of this EST-based gene, and confirmed its transcription start site within CNS1. We hypothesize that this EST is a long noncoding RNA due to low abundance, poor conservation, and absence of significant ORF. Over-expression of a short variant implicates its function in the regulation of target gene transcription, although the mechanism of action remains unknown. We conclude that the risk locus at 8q24.13 harbours a novel EST-based gene that may explain the relationship between GWAS SNPs at this locus and plasma lipid traits.
|
117 |
Functional Analysis of the TRIB1 Locus in Coronary Artery DiseaseDouvris, Adrianna 21 July 2011 (has links)
The TRIB1 locus (8q24.13) is a novel locus associated with plasma TGs and CAD risk. Trib1 is a regulator of MAPK activity, and has been shown to regulate hepatic lipogenesis and VLDL production in mice. However, the functional relationship between common SNPs at the TRIB1 locus and plasma lipid traits is unknown; TRIB1 has not been identified as an eQTL. This cluster of SNPs falls within an intergenic region 25kb to 50kb downstream of the TRIB1 coding region. By phylogenetic footprinting analysis and DNA genotyping, we identified an evolutionarily conserved region (CNS1) within the risk locus that harbours two common SNPs in tight LD with GWAS risk SNPs and significantly associated with CAD. We investigated the regulatory function of CNS1 by luciferase reporter assays in HepG2 cells and demonstrate that this region has promoter activity. In addition, the rs2001844 risk allele significantly reduces luciferase activity, suggesting that altered expression of the EST-based gene may be associated with plasma TGs. We identified an EST within the risk locus directly downstream of CNS1. We performed 5'/3' RACE using HepG2 RNA, identified multiple variants of this EST-based gene, and confirmed its transcription start site within CNS1. We hypothesize that this EST is a long noncoding RNA due to low abundance, poor conservation, and absence of significant ORF. Over-expression of a short variant implicates its function in the regulation of target gene transcription, although the mechanism of action remains unknown. We conclude that the risk locus at 8q24.13 harbours a novel EST-based gene that may explain the relationship between GWAS SNPs at this locus and plasma lipid traits.
|
118 |
Assessment of Novel Molecular Prognostic Markers in Chronic Lymphocytic LeukemiaBin Kaderi, Mohamed Arifin January 2010 (has links)
The clinical course of chronic lymphocytic leukemia (CLL) is highly heterogeneous, which has prompted the search for biomarkers that can predict prognosis in this disease. The IGHV gene mutation status and certain genomic aberrations have been identified as reliable prognostic markers of clinical outcome for this disorder. However, the search for more feasible prognostic markers in CLL is still being pursued. Recently, certain single nucleotide polymorphisms (SNPs) in the GNAS1, BCL2 and MDM2 genes and the RNA expression levels of the LPL, ZAP70, TCL1, CLLU1 and MCL1 genes were suggested as novel prognostic markers in CLL. In papers I-III, we performed genotyping analyses of the GNAS1 T393C, BCL2 -938C>A and MDM2 SNP309 polymorphisms in 268-418 CLL patients and related the genotypes with clinical data. Association studies between the polymorphisms and established prognostic markers (i.e. IGHV mutation status, genomic aberrations, CD38 expression) were also performed. Our studies did not find any significant relationship between these SNPs with either clinical outcome or other known prognostic markers in CLL. In paper IV, we measured the RNA expression levels of LPL, ZAP70, TCL1, CLLU1 and MCL1 in 252 CLL cases and correlated these levels with clinical outcome. Here, we verified that high expression of all these RNA-based markers, except MCL1, were associated with an unfavourable prognosis. We also confirmed a close relationship between IGHV mutation status and the RNA-based markers, especially for LPL and CLLU1 expression. Among the RNA-based markers, multivariate analysis revealed LPL expression as the strongest independent prognostic marker for overall survival and time to treatment. Furthermore, the RNA-based markers could add further prognostic information to established markers in subgroups of patients, with LPL expression status giving the most significant results. In summary, data from papers I-III could not verify the GNAS1 T393C, BCL2 -938C>A and MDM2 SNP309 polymorphisms as prognostic markers in CLL. Future SNP markers must hence be confirmed in large, independent cohorts before being proposed as prognostic marker in CLL. In paper IV, we conclude that LPL expression appears to be the strongest among the RNA-based markers for CLL prognostication. Further efforts to standardize LPL quantification are required before it can be applied in the clinical laboratory to predict clinical outcome in this disease.
|
119 |
Functional Analysis of the TRIB1 Locus in Coronary Artery DiseaseDouvris, Adrianna 21 July 2011 (has links)
The TRIB1 locus (8q24.13) is a novel locus associated with plasma TGs and CAD risk. Trib1 is a regulator of MAPK activity, and has been shown to regulate hepatic lipogenesis and VLDL production in mice. However, the functional relationship between common SNPs at the TRIB1 locus and plasma lipid traits is unknown; TRIB1 has not been identified as an eQTL. This cluster of SNPs falls within an intergenic region 25kb to 50kb downstream of the TRIB1 coding region. By phylogenetic footprinting analysis and DNA genotyping, we identified an evolutionarily conserved region (CNS1) within the risk locus that harbours two common SNPs in tight LD with GWAS risk SNPs and significantly associated with CAD. We investigated the regulatory function of CNS1 by luciferase reporter assays in HepG2 cells and demonstrate that this region has promoter activity. In addition, the rs2001844 risk allele significantly reduces luciferase activity, suggesting that altered expression of the EST-based gene may be associated with plasma TGs. We identified an EST within the risk locus directly downstream of CNS1. We performed 5'/3' RACE using HepG2 RNA, identified multiple variants of this EST-based gene, and confirmed its transcription start site within CNS1. We hypothesize that this EST is a long noncoding RNA due to low abundance, poor conservation, and absence of significant ORF. Over-expression of a short variant implicates its function in the regulation of target gene transcription, although the mechanism of action remains unknown. We conclude that the risk locus at 8q24.13 harbours a novel EST-based gene that may explain the relationship between GWAS SNPs at this locus and plasma lipid traits.
|
120 |
Evaluation of molecular methods used for the rapid detection of multi-drug resistant Mycobacterium tuberculosisHansen, Tarrant William January 2008 (has links)
Tuberculosis remains a major public health issue globally, with an estimated 9.2 million new cases in 2006. A new threat to TB control is the emergence of drug resistant strains. These strains are harder to cure as standard anti-tuberculosis first line treatments are ineffective. Multi Drug Resistant Tuberculosis (MDR-TB) is defined as Mycobacterium tuberculosis that has developed resistance to at least rifampicin and isoniazid, and these strains now account for greater than 5% of worldwide cases. Mutations within the Rifampicin Resistance Determining Region (RRDR) of the rpoB gene are present in greater than 95% of strains that show rifampicin resistance by conventional drug susceptibility testing. As rifampicin mono resistance is extremely rare, and rifampicin resistance is usually associated with isoniaizd resistance, the RRDR region of the rpoB gene is a very useful surrogate marker for MDR-TB. Many molecular assays have been attempted based on this theory and have had varied levels of success. The three methods evaluated in this study are DNA sequencing of the rpoB, katG and inhA genes, the Genotype MTBDRplus line probe assay (Hain Lifesciences) and a novel method incorporating Real-Time PCR with High Resolution Melt analysis targeted at the RRDR using the Rotorgene 6000 (Corbett Lifesciences). The sensitivity for the detection of rifampicin resistance was far better using DNA sequencing or the commercially available line probe assay than detection by the Real-Time PCR method developed in this study.
|
Page generated in 0.1109 seconds